UTI Treatment Market Research Report- Forecast To 2027

UTI Treatment Market Trends, Share And Growth Analysis By Drug Class (Quinolones, Aminoglycosides, Β-Lactam, Azoles And Others), By Clinical Indications (Urethritis, Cystitis, Pyelonephritis), By End User (Hospitals And Self-Administered) - Forecast To 2027

ID: MRFR/Pharma/2268-HCR | February 2021 | Region: Global | 80 pages         

UTI Treatment Market

. Urinary tract infection can affect the lower and upper lines of the urinary tract. Bacterial infection may attack and damage the area

Segmentation

By Drug Class Quinolones Aminoglycosides Ξ’-Lactam Azoles Others
By Clinical Indications Urethritis Cystitis Pyelonephritis
By End User Hospitals Self-Administered

Key Players

  • Pfizer
  • Cipla Inc.
  • GlaxoSmithKline PLC
  • Novartis AG
  • Shionogi & Co. Ltd
  • Novartis AG
  • AstraZeneca
  • Bayer AG

Drivers

  • Female anatomy
  • Sexual intercourse
  • diabetes
  • Obesity etc.
Speak to Analyst Request a Free Sample

UTI Treatment Market Overview 


The UTI treatment market growth rate will approximately reach to USD 9.89 billion in 2023, is projected to rise by 3.6% in the forecast period. Urinary tract infection can affect the lower and upper lines of the urinary tract. Bacterial infection may attack and damage the area. Pain is often experienced during urination if there is an infection in the urinary tract. There are plenty of factors that raise the occurrence of urinary infections.


It is a common disease in many individuals. However, the mortality rate is high due to this infection. There are drugs, therapeutics and indication segments that lead to high demand. Frequent urination feeling even when the bladder is empty can be the cause of infection. Diabetes and obesities are some of the common reasons for these infections.


Due to the rising cases of UTI treatment market is facing high demand. The female population is facing a high rate of this infection in the urinary tract. More than 50% of the women population suffers from this situation. In recent years, the hospitalization due to UTI is 1 million. The advances in urology say that kidney stones are major factors affecting urological health. Patients with kidney disease and stone are more urine to urinal tract infections. In the upcoming years, these factors will lead to a high rate of UTI treatments. 


Covid analysis 


The covid 19 virus is leading to financial instability in global markets. Business and various treatments markets are facing high challenges. Today, the health burden on the healthcare sector is immense in this period. The supply chain disruptions, new developments and manufacturing of drugs are affected. Treatment for UTI is declining in this period. These Infections are non-essential medical treatments.


According to an orthopaedic medical journal, many top doctors are deployed for covid patient care. However, clinical research in the UTI treatment market is growing. It will lead to exceptional developments in the UTI treatment market during the forecast period. All these factors are expected to bring favourable changes in the market. The product line and treatment of the UTI market are expanding. These factors create a positive UTI treatment market scenario post covid 19. 


Market dynamics 


Crucial market drivers 


The Rising rate of kidney stones is a crucial driver of this market. Patients with key issues and diabetes are prone to various infectious. The urinary tract infection can easily attack the patient. Pain during urination and irritation are some of the symptoms in these patients. UTI is a disease that affects more than 15% population. People of all age groups can develop this infection.


This infection can affect the kidney, urethra, bladder and prostate gland of individuals. Using clean toilets is expected to prevent such infections. Maintaining intimate hygiene is another factor that prevents this infection. The prevalence of these infections leads to high adoption of UTI treatment. Furthermore, the launch of combination drugs in the market is the crucial driver.


The combination drugs prove efficient for these infections. The availability of this wide range of therapeutics is expected to boost the UTI treatment market demand. Growth in the geriatric population leads to high demand for the market. The senior population is easily prone to such infections. UTI is widely affecting elderly women over the age of 65 years. The growth of the senior population will have a positive impact in the UTI treatment market. All these UTI treatment market drivers will lead to the exceptional growth rate of the treatments market. 



  • The market growth opportunities 


The new product launches of the market will bring urinary tract infection (uti) treatment market growth. Innovation and new product launches will expand the end-user for the market. Also, the application of the urinary tract infection treatment improves due to the new product launch. The key players are developing new treatments and formulas with effective materials to treat the infections effectively. These futuristic developments in the market will create a wide range of treatment options for the customers. 


In the upcoming years, key players are launching drugs that breakdowns infectious cells. This development will prevent UTI infections from affecting the patient again. This growth factor will raise the supply rates of UTI treatments. The rising Penicillin and Combinations drugs in several regions are estimated to increase growth. Further, the key players are developing new strategies to increase growth. The production of UTI treatment drugs is surging in the forecast period. The launch of a wide range of therapies UTI will attract many end-users. All these factors will contribute to the high revenue rates of the market. 



  • The market restraints 


The side effects related to UTI drugs is a significant market challenge. Most of the clinical drugs for infection come with mild side effects. These side effects are different from patient to patient. Nausea, headache, abdominal pain, vomiting, upset stomach are the side effects of the drug. 


Urinary tract infections are dangerous. To treat the condition strong drugs are prescribed for the patient. Strong components can effectively reduce infection. Due to this, some of the side effects are worse. The fear of side effects, increase hesitation in end users to adopt the technology. Poor knowledge about the benefits and use of UTI treatment is another restrain in the market. These factors can restrict the growth rate. 



  • The market challenges 


Lack of awareness about UTI treatment is a significant market challenge. There are few reliable and licensed drugs in the market that has less awareness. Choosing generic and off-label treatments for the infection can decline the demand for this market. There is a complicated urinary infection that is a severe condition.


For these infections doctors prescribe quinolones. This medication contains plenty of antibodies that can resist bacteria. However, the awareness about these drugs is less among users. Cost-effective alternatives are proffered in many regions. The lack of awareness can decrease the adoption of the UTI drugs market. 



  • The cumulative growth analysis 


The urinary tract infection treatment market trends remain uniform. There is moderate growth leading to a uniform market trend. However, factors that will sustain the UTI treatment market growth are the relevance of kidney stones and the availably of combinations drugs. The combination drugs segment is witnessing high profits.


Penicillin and Combinations is a drug that is effective for UTI. There are a few factors that hamper the demand of the market. The side effects can create a negative impact adoption rate. Also, a lack of awareness will decrease the adoption and supply rates of the market. However, product launches will keep the growth rate stable. 



  • Value chain analysis 


North America will hold the largest urinary tract infection treatment market share. The region will dominate the UTI treatment market with high demand for UTI treatment. Innovations in the diagnostics of the condition will lead to high growth. The research about infections is high in North America.


Colitis is a Bactria that affects most women. It leads to several urinary infections in many individuals. Due to this research, the key player is able to develop a treatment to resist colitis bacteria. The girls' population is witnessing the highest rate of UTI. It is leading to the immense demand for UTI treatment in North America. 


Segment overview 


By drug 



  • Penicillin and Combinations

  • Cephalosporin  

  • Nitrofurans

  • Azoles and Amphotericin B


By indication 



  • Uncomplicated UTI

  • Complicated UTI


By geography 



  • North America 

  • Europe 

  • Asia pacific 

  • South America 

  • Middle East Africa 


Competitive landscape 


The competitive landscape of the UTI treatment market contains strong key players. With new product developments, the completion will be intensive. The key players of the UTI treatment market are increasing product awareness in many regions. These awareness programs will enhance the adoption rate of UTI drugs. Also, market acquisitions, expansion and partnerships will be high in the forecast period. 


Regional analysis 


The UTI treatment market is diversified into Asia Pacific, Europe and North America. Innovational diagnostic procedures will enhance the growth in North America. Also, US and Canada will contribute the highest investments for UTI treatments. The drugs of UTI are effective resistant’s severe bacterial infection in the urinary tract.


Also, Asia pacifies another key player with high shares. The demand for UTI treatment is constantly surging. The development of health infrastructure is boosting overall growth. Also, innovations will lead to new product launches. The cases of UTI are higher in Asia pacific. Europe is the next largest region with more expansion for UTI treatments. The growth potential of the market is high that will bring new developments in upcoming years. 


The key players of the UTI treatment market are 



  1. Pfizer

  2. Cipla Inc.

  3. GlaxoSmithKline PLC

  4. Novartis AG

  5. Shionogi & Co., Ltd

  6. Novartis AG

  7. AstraZeneca

  8. Bayer AG


Recent developments 



  1. The key players in the US are developing an effective treatment for urinary infections in children. This new product portfolio will ring high developments in the market.  



  1. The key players of the UTI treatment market are establishing new products in emerging economies. Europe and Asia pacific are high scope economies that will have high demand. This new establishment will create new end users. 


Report overview 



  1. Market overview highlights 

  2. Analysis based upon COVID 19

  3. Explanation upon the Market Dynamics

  4. Value chain analysis

  5. Market segmentation overview

  6. The regional analysis

  7. Competitive landscape analysis

  8. Recent Developments



Report Scope:
Report Attribute/Metric Details
  Market Size   2023: USD 9.89 Billion
  CAGR   3.6% (2018-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Drug Class, Clinical Indications, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Bayer AG, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Cipla Inc., Dr. Reddy’s Laboratories Ltd., Johnson & Johnson GlaxoSmithKline and others.
  Key Market Opportunities

  • Growing health awareness
  • Rising incidence of obesity
  •   Key Market Drivers

  • Female anatomy
  • Sexual intercourse, diabetes
  • Obesity etc.


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The UTI treatment market is projected to grow at a 3.6% CAGR between 2018-2023.

    The US is predicted to lead the UTI treatment market.

    The UTI treatment market is predicted to touch USD 9.89 billion by 2023.

    Growing health awareness and rising incidence of obesity are adding market growth.

    Unmet clinical needs may limit market growth.